Millennium 4Q Revenues: $140.1 million (+15%) 4Q Earnings: $8 million (loss of $43.9 million 4Q2005) FY Revenues: $486.8 (-13%) FY Loss: $44 million (loss of $198.2 million FY2005) Comments: For the year, Velcade sales in the U.S. were $220.5 million, up 15%. Narrowed loss is attributed to the increase in U.S. Velcade sales, the decrease in operating expenses, and a $56.7 million reduction in restructuring charges. In December 2006, the FDA granted full approval of Velcade...